Clinical trial · Observational
An Analysis of Urinary Proteases as Biomarkers for Hepatocellular Carcinoma-101423
NCT01316679CI-TRIAL-00026949completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Specific urine proteases or groups of these enzymes can be reliable biomarkers and an effective gauge of response to therapy in patients with hepatocellular carcinoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Liver Disease | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- group A
- description
- Patients with known HCC
- label
- Group B
- description
- Patients with liver disease but no HCC
- label
- Group C
- description
- Control; patients with no known liver disease or HCC
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Ability and willingness to provide written informed consent * Must be between 18-90 years of age at the time of consent * Ability to provide urine specimen at protocol-defined timepoints * Must have treatment interventions planned that are directly related to liver disease (excluding those assigned to group 3-Controls) Exclusion Criteria: * Suspected inability, e.g. unwillingness to comply with study procedures or unwillingness to provide written consent
References
Publications (0)
Data not yet available
No reference posted for this study.